…we recommend Ivermectin for treatment of covid-19 in early out-patient disease at a dose of 0.2 mg/kg – 0.4 mg/kg and for later phase, hospital patients 0.4 mg – 0.6 mg/kg. In each phase, the higher dose range should be used in more severe illness.
Read the full statement
Share:
The team at Bird are transparent in our operations. Bird is a campaign managed through EbMCsquared, a not-for-profit Community Interest Company. It means 100% of profits after tax are reinvested into the business or to the advancement of our social purpose, for example to work on projects such as the Ivermectin campaign. We are here to promote and provide evidence for health and wellbeing, to inform decision-making on matters of public health and safety. We do this to advance health and wellbeing for the benefit of humankind.
Nothing on this Website provides medical advice or any form of diagnosis or treatment of any kind to web users. Medical decisions should be made by the patient’s physician who can consider a review of the BIRD materials and knowledge of the patient’s medical history and condition. All information provided on the BIRD website or in connection with the Website are offered to promote consideration by trained health care professionals of possible treatments and for general informational purposes and are not medical advice to users. Errors and Omissions excepted.
Please support our campaign with a monthly or a single amount to help us keep pressure on authorities to approve the safe drug ivermectin that will help beat covid-19 and save lives around the world.
Bird Group/EBMC Squared is a not-for-profit Community Interest Company (CIC).
All funds received will be invested in our activities to promote public health and wellbeing.
Your monthly or single contribution will help us keep pressure on authorities to approve the safe drug ivermectin that will help beat covid-19 and save lives around the world.
